$2.12 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Buy | UNITEDHEALTH GROUP INC | $150,244,000 | -4.1% | 603,100 | +2.4% | 7.09% | +25.0% |
| WCG | Buy | WELLCARE HEALTH PLANS INC | $91,957,000 | +21.8% | 389,500 | +65.4% | 4.34% | +58.8% |
| ISRG | Buy | INTUITIVE SURGICAL INC | $72,796,000 | -10.3% | 152,000 | +7.5% | 3.44% | +16.9% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $60,918,000 | -13.4% | 4,476,000 | +3.5% | 2.88% | +12.8% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $58,385,000 | -15.5% | 599,500 | +49.9% | 2.76% | +10.2% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $56,314,000 | -29.0% | 788,600 | +22.3% | 2.66% | -7.4% |
| EHC | Buy | ENCOMPASS HEALTH CORP | $44,733,000 | -15.2% | 725,000 | +7.2% | 2.11% | +10.6% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $35,686,000 | -28.8% | 327,000 | +5.3% | 1.68% | -7.3% |
| LOXO | Buy | LOXO ONCOLOGY INC | $33,827,000 | -2.4% | 241,500 | +19.0% | 1.60% | +27.3% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $33,639,000 | -11.0% | 203,000 | +3.6% | 1.59% | +16.1% |
| TFX | Buy | TELEFLEX INC | $33,602,000 | +1.8% | 130,000 | +4.8% | 1.59% | +32.7% |
| IRTC | Buy | IRHYTHM TECHNOLOGIES INC | $33,489,000 | -26.3% | 482,000 | +0.4% | 1.58% | -3.9% |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $32,336,000 | +5.0% | 915,000 | +14.4% | 1.53% | +36.9% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $28,107,000 | -10.3% | 183,500 | +1.9% | 1.33% | +16.9% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $23,158,000 | -6.0% | 900,750 | +28.7% | 1.09% | +22.5% |
| ALGN | Buy | ALIGN TECHNOLOGY INC | $21,990,000 | -16.7% | 105,000 | +55.6% | 1.04% | +8.6% |
| IDXX | Buy | IDEXX LABS INC | $20,555,000 | -1.4% | 110,500 | +32.3% | 0.97% | +28.5% |
| BAX | Buy | BAXTER INTL INC | $19,792,000 | -13.6% | 300,700 | +1.2% | 0.93% | +12.7% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $18,479,000 | +21.0% | 425,000 | +112.5% | 0.87% | +57.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $17,100,000 | +36.6% | 178,000 | +7.9% | 0.81% | +78.1% |
| MDCO | Buy | MEDICINES CO | $13,913,000 | -32.6% | 726,900 | +5.3% | 0.66% | -12.0% |
| XENT | Buy | INTERSECT ENT INC | $13,104,000 | -0.9% | 465,000 | +1.1% | 0.62% | +29.2% |
| AXGN | Buy | AXOGEN INC | $12,339,000 | -38.4% | 603,970 | +11.1% | 0.58% | -19.7% |
| A | Buy | AGILENT TECHNOLOGIES INC | $12,332,000 | +6.5% | 182,800 | +11.4% | 0.58% | +38.9% |
| EXEL | Buy | EXELIXIS INC | $12,223,000 | +15.9% | 621,400 | +4.4% | 0.58% | +51.0% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $11,518,000 | -26.2% | 213,658 | +6.8% | 0.54% | -3.7% |
| SGEN | New | SEATTLE GENETICS INC | $11,474,000 | – | 202,500 | +100.0% | 0.54% | – |
| IMMU | Buy | IMMUNOMEDICS INC | $11,131,000 | -31.0% | 780,000 | +0.6% | 0.52% | -10.1% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $10,984,000 | -9.4% | 129,000 | +3.2% | 0.52% | +18.0% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $10,660,000 | -36.6% | 500,000 | +17.6% | 0.50% | -17.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $10,057,000 | +76.4% | 245,000 | +63.3% | 0.48% | +130.6% |
| EPZM | Buy | EPIZYME INC | $9,902,000 | -24.7% | 1,607,500 | +29.5% | 0.47% | -1.9% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $9,824,000 | -23.1% | 1,329,400 | +51.1% | 0.46% | +0.2% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $9,660,000 | -27.0% | 4,200,000 | +1.8% | 0.46% | -4.8% |
| GH | New | GUARDANT HEALTH INC | $8,119,000 | – | 216,000 | +100.0% | 0.38% | – |
| IFRX | Buy | INFLARX NV | $7,925,000 | +30.1% | 217,900 | +22.8% | 0.37% | +69.2% |
| FRPT | New | FRESHPET INC | $7,558,000 | – | 235,000 | +100.0% | 0.36% | – |
| NVCR | Buy | NOVOCURE LTD | $6,529,000 | +398.4% | 195,000 | +680.0% | 0.31% | +555.3% |
| ODT | Buy | ODONATE THERAPEUTICS INC | $6,266,000 | -25.9% | 445,000 | +2.2% | 0.30% | -3.3% |
| AXNX | New | AXONICS MODULATION TECH INC | $6,044,000 | – | 400,000 | +100.0% | 0.28% | – |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $5,820,000 | -7.2% | 216,500 | +0.7% | 0.28% | +21.1% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $3,477,000 | +4.6% | 380,000 | +41.8% | 0.16% | +36.7% |
| PHAS | New | PHASEBIO PHARMACEUTICALS INC | $2,580,000 | – | 835,000 | +100.0% | 0.12% | – |
| CGEN | Buy | COMPUGEN LTDord | $2,387,000 | -42.5% | 1,100,000 | +2.0% | 0.11% | -24.7% |
| PTI | New | PROTEOSTASIS THERAPEUTICS IN | $1,296,000 | – | 400,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.